Spanish Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil
Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 51
  • Journal CiteScore: 46.50
  • Journal Impact Factor: 26.99
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Google Scholar citation report
Citations : 12061

International Journal of Drug Development and Research received 12061 citations as per Google Scholar report

Flyer image
International Journal of Drug Development and Research peer review process verified at publons
Flyer image
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
View More
Share This Page

HAase sensitive dual-targeting irinotecan liposomes enhance the therapeutic efficacy of lung cancer in animals

17th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems
October 04-06, 2018 Moscow, Russia

Liang Zhang and Haixin Cui

Institute of Environment and Sustainable Development in Agriculture-CAAS, China

Posters & Accepted Abstracts: Int J Drug Dev & Res

Abstract:

Among all cancers, lung cancer is one of the most common and serious types of cancer. It is challenging for site-specific delivery of anticancer therapeutics to tumor cells. Herein, we developed a novel “smart” dual-targeting liposomal platform to respond to the highly expressed hyaluronidase (HAase) in the tumor microenvironment and improve tumor targeting and antitumor efficacy. In our design, the HA was used as a sensitive linker between a liposomal lipid and long chain PEG block to synthesize three functional conjugates in order to prepare “smart” liposomal platform modified with epidermal growth factor receptor (EGFR) antibody (GE11) and cell-penetrating peptide (TATp). Using irinotecan as a model therapeutic, evaluations were performed on the human lung adenocarcinoma A549 cells as well as the xenografted A549 cancer cells in nude mice. The GE11/HA/TATpirinotecan liposomes evidently increased the uptake of irinotecan and showed significant anti -tumor efficacy in the xenografted A549 cancer cells in nude mice by intravenous administration. The mechanisms were defined to be two aspects: GE11 exhibits high affinity for EGFR binding and the degradation of the HA by HAase results in the long-chain PEG removal and exposure of the previously hidden surface-attached TATp to enhance the target cell internalization. Our findings suggest that this functional liposomal platform may provide a novel strategy for treating lung cancers because of effective intracellular delivery.

Biography :

Liang Zhang has completed his PhD at Peking University and Postdoctoral fellow at University of Texas Southwestern Medical Center. He is the Chief Scientist of Nanotechnology Research Center of Agriculture. His current research is focusing on development of multifunctional nanoparticles for targeted therapy.

E-mail: zhangliang02@caas.com

PDF HTML